ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Caixin

Fosun and BioNTech to develop vaccine targeting omicron

Many drugmakers expect efficacy of existing jabs lower against new variant

Fosun is the exclusive partner of BioNTech for marketing the co-developed mRNA vaccine in greater China, which includes Hong Kong, Macao and Taiwan.   © Reuters

Shanghai Fosun Pharmaceutical said it will work with German partner BioNTech to develop a new vaccine targeting the omicron variant of COVID-19, but it may take three to four months to win regulatory approval.

Fosun is the exclusive partner of BioNTech for marketing the mRNA vaccine co-developed by BioNTech and U.S. drug giant Pfizer in greater China, which includes Hong Kong, Macao and Taiwan. Known in China as the Comirnaty vaccine, the product has not been approved for the Chinese mainland.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more